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Reducing agentcentered oxidative catalysis has been overlooked in the research of the copper
complexes of the Alzheimer's disease-related β-amyloid (Aβ) peptides. Cu2+ complexes of Aβ1–40 and its 1–16
and 1–20 fragments have recently been shown to exhibit signiﬁcant metal-centered oxidative activities
toward several catecholamine neurotransmitters with and without H2O2 around neutral pH [G.F.Z. da
Silva, L.-J. Ming, “Metallo-ROS” in Alzheimer's disease: metal-centered oxidation of neurotransmitters by
CuII–β-amyloid and neuropathology of Alzheimer's disease, Angew. Chem. Int. Ed. 46 (2007) 3337–3341].
The results further support the metallo-Aβ-associated oxidative stress theory often considered to be
connected to the neuropathology of the disease. The metal-centered oxidative catalysis of CuAβ1–16/20
challenges the long-standing proposed redox role of Met35 in Aβ because Aβ1–16/20 do not contain a Met.
External Met has been determined by kinetic, optical, and electron paramagnetic resonance methods to bind
directly to the Cu2+ center of CuAβ1–40 and CuAβ1–20 with Kd=2.8 mM and 11.3 μM, respectively, which reﬂects
less accessibility of the metal center in the full-length CuAβ1–40. However, Met does not serve as a reducing
agent for the Cu(II) which thus must amplify the observed oxidative catalysis of CuAβ1–20 through a non-redox
mechanism. Conversely, the CuAβ-catalyzed oxidation reaction of dopamine is inhibited by bio-available
reducing agents such as ascorbate (competitive Kic=66 μM) and glutathione (non-competitive, Kinc=53 μM).
These data indicate that the oxidation chemistry of metallo-Aβ is not initiated by Met35. The results yield
further molecular and mechanistic insights into the roles of metallo-Aβ in this disease.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionOxidative stress has been a key topic of research concerning cancer,
aging, heart diseases, arthritis, diabetes, and neurodegenerative
disorders such as Parkinson's and Alzheimer's diseases (AD) [1–6].
Mechanisms proposed for the neurodegeneration in the brain of AD
patients generally focus on the β-amyloid peptide (Aβ), a proteolytic
product of 40–42 amino acids of the ubiquitously distributed amyloid
precursor protein (APP), and its complexes of redox-active metal ionsmer's diseases; APP, amyloid





ces Center at Houston, 6431
l rights reserved.[7,8]. The “Aβ cascade hypothesis” suggests that Aβ aggregates trigger
a complex pathological cascade which leads to neurodegeneration in
AD [9], including generation of H2O2 [10–12], free-radical induced
oxidation [13–15] such as lipid peroxidation [16], and the involvement
of Met-35 as a reducing agent [17–22] in the redox chemistry of
metallo-Aβ. A central focus of the neuropathology of AD thus has been
the effects of redox-active transition metal ions and reactive oxygen
species (ROS), such as superoxide, hydroxyl free radical, and H2O2
[7,8]. Although physiological processes responsible for dealing with
ROS can be up-regulated to tackle variations in oxidative stress
[23,24], long-term effects of such chemical imbalance have been
speculated [1–5]. Some AD treatment strategies have targeted the
metal center in metallo-Aβ to prevent peptide aggregation and ROS
generation [25–28] and the role of the metal therein was proposed
[29,30]. However, comparatively little effort has been focused on the
mechanism for the metal-centered chemistry, besides the production
of H2O2, which renders direct substrate binding and oxidation by the
metal center. If metal-mediated ROS generation is one of the leading
causes of oxidative stress, the formation of ROS at the metal site as
well as the reactivity of the “metallo-ROS” center [31] in CuAβ may
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Nevertheless, there are still debates on different views about the role
of metalloamyloids even very recently [32].
Although A-beta accumulation is not likely to be the only factor
involved in neuronal cell death, transgenic mousemodels with human
A-beta have provided signiﬁcant insights into the neuropathology of
AD and behaviors of AD patients, including Aβ aggregation and loss of
memory [33–35]. Rodent Aβ has been shown to exhibit redox activity
in vitro that was attributed to ROS generation via Met35 [36], even
though the metal-binding residues were not fully conserved in rodent
Aβ (i.e., His13→Arg). Since Aβ activity and aggregation in AD brains is
sequence-speciﬁc and metal-dependent [7,8], it is a priority to
establish the targets of redox activity that can contribute to the
physiological and cognitive effects of AD.We have recently established
that the CuII complexes of Aβ and its soluble fragments (Aβ1–16 and
Aβ1–20) showed considerable activities toward the oxidation of
phenol, polyphenol, catechol, and their derivatives to form o-quinones
via a type-3 copper-centered mechanism [31,37,38]. Such reactivities
can explain the mechanism for the formation of dityrosine in Aβ [39]
via activation of the phenol side chain and also challenge the redox
role of Met35 that is not present in the fragments.
Herein we present kinetic and spectroscopic investigations of the
oxidation chemistry of CuAβ1–20 and the inﬂuences of exogenous
methionine and reducing agents on its oxidative activity. The results
corroborate metal-centered oxidative stress and shed light on the
mechanistic roles of Met-35 and reducing agents in the oxidation
chemistry of CuAβ.
2. Materials and methods
The 1–20 fragment of Aβ was synthesized by the use of the Fmoc
chemistry at the Peptide Center of the University of South Florida,
and the identity of the peptide conﬁrmed with a Bruker MALDI-TOF
mass spectrometer. Aβ1–40 was obtained from EZBiolab (Westﬁeld,
IN). The Cu(II) complexes of Aβ were prepared by addition of 1
equivalent of Cu(II) directly into the peptide solution under
experimental conditions, wherein the Aβ1–40 peptide was dissolved
with sonication followed by removal of the undissolved residue with
centrifugation. Dopamine, ascorbic acid, and glutathione (GSH) were
obtained from Sigma-Aldrich (St. Louis, MO), 3-methyl-2-benzothia-
zolinone hydrazone hydrochloride monohydrate (MBTH) from Acros
(Fairlawn, NJ), and H2O2, EDTA, L-methionine, and Cu(NO3)2 from
Fisher Scientiﬁc (Suwanee, GA). All plastic ware and glassware were
demetallized with EDTA and extensively rinsed with 18.0-MΩ
deionized water.
The catechol oxidase assay toward dopamine was performed as
previously reported [31,40]. Equal concentrations of dopamine and
the o-quinone indicator MBTH were mixed in 100 mM HEPES at pH
7.00 in a ﬁnal volume of 1.0 mL. The MBTH-adduct of o-quinone was
monitored at 505 nm (ɛ=27,200 M−1 cm−1) and 25 °C for 5–10 min
with a Varian CARY50 Bio-UV–Vis spectrophotometer equipped with
a CARY PCB-150Water Peltier temperature regulation system, and the
rates determined by the change in absorbance over time. The rates
were ﬁtted to appropriate rate laws, such as the Michaelis–Menten-
like kinetics [41], and rate constants determined with non-linear
regression. The effects by H2O2, ascorbate, GSH, and L-Met were
determined similarly in the presence of different amounts of the
corresponding reagent and the inhibition/dissociation constants
determined accordingly. Binding of L-Met to CuAβ1–20 was performed
by direct titration of Met into CuAβ1–20 in 100 mM HEPES at pH 7.0
and monitored with the CARY50 spectrophotometer. NMR measure-
ments were performed on a Varian Unity-500 spectrometer.
EPR experiments of the samples under the conditions of the kinetic
experiments were performed on a Bruker Elexsys E580 cw/pulsed X-
band spectrometer. A typical cw EPR spectrum was obtained with a
microwave frequency of 9.4 GHz, ﬁeld modulation ∼2 G, and timeconstant of 40–80 ms at ∼5–6 K. The g and A tensors were obtained
with numerical ﬁttings using the “easyspin” toolbox for Matlab [42].
ESEEM (electron spin echo envelope modulation) spectra were
recorded with the usual π/2-τ- π/2-T- π/2 pulse sequence and a π/2
pulse of 20 ns. A typical ESEEM spectrum consists of 1024 points taken
at time intervals of 8 ns. The transient was ﬁrst base-line corrected by
subtracting the ordinary T1 exponential decay function and any
remaining constant baseline offset, then zero-appended to 2048
points. A Hamming window function was then applied to the time-
domain spin-echo envelope, followed by Fourier transformation to
afford the frequency-domain spectrum.
An ESEEM spectrum can reveal those nuclei having super-
hyperﬁne coupling with the CuII center, including coordinated His
side chains and water [43]. In the case of coordinated His side chains,
the super-hyperﬁne coupling arises from the electron-nuclear inter-
actions and the nuclear quadrupole interactions (NQI) of the remote
non-coordinated nitrogen (14N, I =1) on the imidazole ring of
coordinated His side chains. At X-band, three zero-ﬁeld nuclear
quadrupole resonance lines ν± and νo are observed which can be
determined from the NQI lines in the ESEEM spectrum (Eqs. (1) and
(2)), wherein e2qQ is the quadrupole coupling constant and η the
asymmetry parameter (η=0 for a complete axial symmetry and 1 for a
pure rhombic symmetry).
vF = 1=4ðe2qQÞð3FηÞ ð1Þ
vo = 1=2ðe2qQÞη ð2Þ
The e2qQ and η values can be obtained from the NQI lines in the
ESEEM spectra and Eqs. (1) and (2), i.e., (ν+−νo /2) /3=1/4(e2qQ). In the
case of coordinatedwater, the super-hyperﬁne coupling can arise from
deuterium atoms of deuterated water. The deuterium Zeeman
interaction at X-band is much larger than the isotropic component
of the electron-nuclear coupling. Thus, the deuterium peak in the
ESEEM spectrum is found at the deuterium Zeeman frequency and
split slightly by the electron-nuclear coupling.3. Results
Dopamine is oxidized by CuAβ1–20 in the absence of H2O2 with rate
constants kcat=0.0104 s−1 and Km=0.89 mM (lowest trace ●, Fig. 1A),
consistent with the metal-centered pre-equilibrium kinetics pre-
viously observed [31]. Addition of the amino acid L-Met to the reaction
solution signiﬁcantly increases the oxidative activity (Fig. 1A, B),
which seems to also induce slight cooperativity, e.g., the activity
proﬁle with saturating amount of Met gives a Hill's coefﬁcient θ=2.3
(trace □, Fig. 1A). The activity reaches a plateau at high [Met],
indicating direct Met binding to CuAβ1–20 in the presence of the
substrate (S) dopamine. Fitting of the kcat values as a function of [Met]
to a simple equilibrium of [CuAβ-S + Met→Met-CuAβ-S] (which is
followed by product formation) gives an afﬁnity constant of 3900 M−1
(i.e., Kd=0.26 mM). Met follows a non-essential activation pattern
toward dopamine oxidation by CuAβ1–20 as shown in the Lineweaver–
Burk plot (Fig. 1C), i.e., both CuAβ1–20-S and Met-CuAβ1–20-S
complexes are active. From the data, the dissociation constants KAc
and KAu for the complexes Met-CuAβ1–20 and Met-(CuAβ1–20-S) can
be obtained to be 0.087 and 0.125 mM, respectively. The latter is close
to the value obtained from the ﬁtting of the activity with respect to
Met binding to the pre-equilibrium complex (CuAβ1–20-S) from the
kinetic measurements.
The activity is further enhanced in the presence of H2O2. Note that
both Met and H2O2 can activate dopamine oxidation and are not
exclusive of each other, but showing a combined effect, i.e., the kcat
value of 0.180 s−1 in the presence of saturating amount of Met and
H2O2 (Fig. 1D) is a combination of 0.088 s−1 for Met activation and
0.099 s−1 for H2O2 activation. This observation reﬂects plausible
independent activation mechanisms of Met and H2O2. A much more
Fig. 3. Optical titration of L-methionine into 0.20 mM CuAβ in 100.0 mM HEPES pH 7.0.
The insets show the d–d transition and ﬁtting of the data to Met binding to CuAβ1–20
with a stoichiometry of 1:1.
Fig. 1. (A) Rates of dopamine oxidation by 2.75 μM CuAβ1–20 with [Met] of 0, 1.0, 2.0, 4.0,
7.5, and 10.0 mM (from bottom) in 100.0 mM HEPES at pH 7.0 and their ﬁtting with the
Michaelis–Menten equation (dotted traces) and with the Hill equation (solid traces),
which yields the rate constants for the kcat-vs.-[Met] plot in (B). (C) The Lineweaver–
Burk plot which clearly shows a non-essential activation pattern of Met (0, 1.0, 2.0, 4.0,
7.5, and 10.0 mM from top) toward dopamine (S) oxidation under the same conditions
as in (A). (D) Rate of dopamine oxidation by 5.0 μM CuAβ1–20 in the presence of
saturating amounts of L-Met and H2O2 as in (A).
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without H2O2 (Fig. 1A), yielding θ=4.1.
As opposed to Met, the reducing agents ascorbic acid and GSH act as
inhibitors toward dopamine oxidation by CuAβ1–20 (Fig. 2), however, with
different inhibition patterns. Herein, GSH was determined to be a non-
competitive inhibitor with an inhibitor constant Kinc=53 μM; (Fig. 2A);
whereas ascorbic acid was revealed to be a competitive inhibitor with an
inhibition constant Kic=66 μM (Fig. 2B).
Upon addition of Met, the electronic spectrum of CuAβ1–20 exhibits
an intense charge-transfer transition at 316 nm (Fig. 3). Such charge-
transfer transition is not observed in the full-length CuAβ1–40,Fig. 2. (A) Glutathione (10.0 μM, 20.0 μM, and 40.0 μM from bottom) and (B) ascorbic
acid inhibition (0.0, 0.12, 0.55, and 0.95 mM from bottom) toward dopamine oxidation
by 2.75 μM Cu–Aβ1–20 in 100.0 mM HEPES pH 7.0.suggesting that Met35 does not interact with the CuII center. The d–d
transition of CuAβ1–20 at 600 nm is not signiﬁcantly affected in the
presence of saturating amounts ofMet (Fig. 3; inset). The change in the
intensity of the charge transfer transition as a function of [Met] can be
ﬁtted to the 1:1 binding pattern of [CuAβ1–20 + Met→Met-CuAβ1–20]
to yield a dissociation constant Kd=11.3 μM (Fig. 3, inset).
The X-band EPR spectrum of CuAβ1–20 can be well ﬁtted to an axial
magnetic environment with g// =2.268, g⊥=2.064, A// =547, and
A⊥=51.1 MHz (Fig. 4A). These values are consistent with those
reported for CuII complexes of Aβ and fragments [44], e.g., g//=
2.265–2.269, g⊥=2.059–2.062, and A//=465–577 MHz. As opposed to
the dramatic change in the electronic spectrum, the EPR spectrum
changes only slightly to g// = 2.257, g⊥ =2.059, A// = 565, and
A⊥=35.8 MHz upon Met binding (Fig. 4A).
The X-band ESEEM spectrum of CuAβ1–20 (solid trace; Fig. 4B)
reveals three 14N NQI lines at νo=0.33, ν−=1.11 (shoulder), and
ν+=1.45 MHz (Eqs. (1) and (2)), the double-quantum transitions at
∼4 Mz, and the combination lines at 2.33, 2.95, and 3.45 MHz. From
which, an average e2qQ value is obtained to be 1.71MHz, a value found
for a coordinated His [43], and a small η value of 0.39. The ν− line can
be better determined once the values of e2qQ and η are determined
from νo and ν+. At least one coordinated water is revealed which
attributes to the deuterium modulation at 2.29 MHz when the
spectrumwas acquired from a sample in D2O buffer excited at 3391 G
(dashed trace, Fig. 4B), consistent with 2H resonance of 2.21 MHz at
this ﬁeld. This small discrepancy may be attributed to the presence of
a small super-hyperﬁne coupling [43]. A spectrum for Met-bound
CuAβ1–20 in D2O buffer was acquired under the same conditions
(dotted trace, Fig. 4B) to investigate the status of the coordinated
water uponMet binding. The 14N NQI lines change only slightly, found
at νo=0.15, ν−=1.22 (shoulder), and ν+=1.37 MHz which afford
e2qQ=1.73 MHz and a small η=0.17 (which seems too small that
might be attributed to the large uncertainty of the small νo value). The
deuterium line is observed at 2.19 MHz when excited at 3351 G, rightFig. 4. (A) X-band EPR spectra of CuAβ1–20 in the presence (top) and absence (bottom) of
L-Met and the simulated spectra (dashed traces). (B) ESEEM spectra of 1.0 mM CuAβ1–20
in 50.0 mM HEPES buffer in H2O pH 7.0 (solid trace) and in D2O (dashed trace) at pH(D)
7.0 and after addition of 8.0 (mM) Met (dotted trace).
Fig. 5. (A) Oxidation of dopamine by 2.8 μM CuAβ1–40 in the air in the presence (●) and
absence (Δ) of 15mMMet at pH 7.0 (HEPES 0.1M). The solid traces are ﬁttings to the Hill
equation while the dotted trace is to the Michaelis–Menten equation. (B) The inﬂuence
of Met on the oxidation of 5 mM dopamine by 2.8 μM CuAβ1–40 in the presence (◯) and
absence (Δ) of 40 mM H2O2 at pH 7.0 (HEPES 0.1 M).
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super-hyperﬁne coupling.
The Cu(II) complexes of Aβ1–40 and its fragments (1–16 and 1–20)
have been demonstrated to exhibit type-3-copper-like oxidative
activities in our previous studies; however, subtle differences among
these CuAβ complexes of different lengths are still present, such as
their different activities toward catechol- and phenol-containing
substrates as well as interactions with and activations by lipid
micelles to different extents [31,37,38]. Thus, it is also important to
determine the inﬂuence of Met on Cu–Aβ1–40 to reveal the similarities
and differences from its 1–16 and 1–20 fragments. The oxidation of
dopamine by Cu–Aβ1–40 affords kcat=1.98×10−3 s−1 and Km=0.68 mM
(Δ; Fig. 5A), comparing to kcat=0.0104 s−1 and Km=0.89 mM for
dopamine oxidation by Cu–Aβ1–20 under the same conditions (lowest
trace ●, Fig. 1A). The presence of 15 mM Met does not signiﬁcantly
change the oxidative activity toward dopamine (●; Fig. 5A), affording
kcat=2.9×10−3 s−1 and Km=2.6 mM (or ﬁtted with the Hill equation to
afford kcat=1.91×10−3 s−1 and Km=1.2 mM and a slight cooperativity
with θ=1.54). At most less than 15% increase in activity was observed
at [dopamine]=5 mM and [Met]=15 mM (Δ; Fig. 5B). Conversely, the
addition of Met decrease the enhancement effect of 40 mM H2O2 (◯;
Fig. 5B), affording an activity only about twice higher than that in the
absence of H2O2 at [Met]=15 mM (Δ; Fig. 5B). The binding of Met to
CuAβ1–40 was monitored via electronic transitions, wherein the
increase in intensity at ∼300 nm as a shoulder reaches a saturation
at N3mM (Fig. 6) with a dissociation constant of 2.8 mM (inset, Fig. 6),
analogous to the results in Met titration (◯; Fig. 5B), which is much
larger than that for Met binding to Cu–Aβ1–20 (11.3 μM; inset plot in
Fig. 3). Moreover, the d–d transition at ∼620 nm is shifted to ∼720 nmFig. 6. Change in electronic spectrum of CuAβ1–40 (0.14 mM in 0.1 M HEPES at pH 7.0)
upon addition of L-Met and the plot of the change in the absorption of the shoulder at
300 nm therein (inset).at [Met]N3 mM (inset, Fig. 6), different from the persistent d–d
transition upon Met binding to Cu–Aβ120.
4. Discussion
Metabolic malfunctions of catecholamine neurotransmitters have
been suggested to be related to the neuropathology of AD [45–48]. Of
these neurotransmitters, dopamine is also known to directly link to
the neurodegenerative Parkinson's disease [49] and has been
proposed to be associated with adult neurogenesis in the subven-
tricular zone [50,51]. We have recently shown that CuAβ can catalyze
oxidation of catecholamine neurotransmitters, including dopamine
[31], to generate neurotoxic quinone products [52–54]. The oxidation
of catechol and phenol and their derivatives by the CuII complexes of
Aβ1–40, Aβ1–20, and Aβ1–16 in the presence or absence of H2O2 was
demonstrated to be consistent with the mechanism of type-3 copper
oxidases such as di-Cu catechol oxidase (Fig. 7) [31,37,38]. Therein, the
catechol-containing substrate binds to a presumed transient di-CuII
active center (step i) and is oxidized to o-quinone via 2-electron
transfer to afford a di-CuI active center (C and step ii). The di-CuI center
can bind O2 (step iii) to form a μ-η2:η2 peroxo-CuII2 center shown in D
(or its isoelectronic counterparts, oxy-di-CuI, μ-η1:η1-hydroxyperoxo-
di-CuII, and bis-μ-oxo-di-CuIII) as demonstrated in enzyme [55] and
chemical model systems [56,57], which may bind and oxidize the
substrate (steps iv and v). The presence of a reducing agent such as
ascorbic acid can thus facilitate the aerobic pathway to yield the di-CuI
active center (C) ready for O2 binding and H2O2 production (step vi)
[10,12]. Moreover, the inhibitory effects of ascorbic acid and GSH
described herein point to a different mechanism for their action. The
binding of ascorbic acid as a competitive inhibitor to themetal in CuAβ
that prevents the oxidative catalysis is also consistent with the
“antioxidant” role of CuAβ toward ascorbate oxidation previously
suggested [58]. A short-cut route analogous to the “peroxide shunt” in
heme-containing peroxidase [59] can take place to form the μ-peroxo-
CuII2 center upon H2O2 binding (step vii), followed by substrate
binding and oxidation (step iv and E). The ternary complex E can also
be formed upon H2O2 binding to the intermediate B (step viii),
representing a random bi-substrate mechanism.
Met35 in Aβ1–40 has been suggested to serve as a reducing agent
[17–22] responsible for the initiation of the redox cycling of the CuII
center in CuAβ1–40 which leads to H2O2 production (i.e., step vi inFig. 7. One plausible mechanism for the catechol oxidase-like activity of CuAβ toward
the oxidation of dopamine. The route vii, vi, and v represent a “peroxo shunt” pathway.
X is an exogenous ligand such as a bound Met. A monodentate bridging peroxo/
hydroxyperoxo binding mode may also be an appropriate intermediate at D and E to
reduce the coordination crowding upon binding of Met, H2O2, and the substrate,
wherein the proton of the hydroxyperoxo can be obtained from the catechol substrate.
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sulfoxide form in Aβ1–40 has been proposed to be involved in
aggregation, lipid peroxidation, and redox chemistry in association
with themetal center [17–22]. In the case of the CuAβ1–20 complex, the
activation proﬁle of [Met] (Fig. 1) and the optical spectrum (Fig. 3)
indicate direct Met binding to the metal in the complex which
potentially can reduce the CuII center as proposed previously for
Met35. In this case, the amount of di-CuI (C) would increase which in
turn would increase the amount of the μ-peroxo-CuII2 center upon O2
binding (D; step iii) and complete the catalytic cycle upon substrate
binding (iv and v). Once CuAβ1–20 is reduced, it cannot follow the
peroxide shunt pathway anymore. Our observation that H2O2 can still
signiﬁcantly enhance the activity in the presence of a saturating
amount of Met (Fig. 1B) and has an additive effect with Met on the
activity suggests that the CuII center is not signiﬁcantly reducedbyMet.
Moreover, the difference in electrode potentials between CuII-Aβ and
Met is 0.71 V [60], which gives a dramatic 68.5 kJ difference in Gibbs
free energy that is equivalent to a negligibly small equilibriumconstant
of 9.8×10−13 for one-electron reduction of CuII-Aβ1–20 byMet at 298 K.
The binding ofMet to CuII-Aβ1–20 does not renderMet oxidationwithin
a couple of weeks under the experimental conditions based on its
virtually unchanged methyl NMR signal (data not shown), further
concluding the non-redox active role ofMet. Thus, the observedMet35
oxidation in CuAβ1–40/42 is most likely to be attributed to other
mechanisms which may not be observable under our experimental
conditions and time frame, rather than being a reducing agent directly
involved in the Cu-centered oxidation chemistry. In the case of the
CuAβ1–40 complex (Figs. 5 and 6), the external Met does not
signiﬁcantly enhance the activity as in the case of CuAβ1–20 and
exhibits a competitive manner with H2O2 as opposed to the additive
pattern in the latter case. This observation suggests that the folding of
the peptides chain in these two complexes may be different which
renders the metal active center less accessible in the case of CuAβ1–40
which results in signiﬁcant decrease in Met afﬁnity and less room for
the binding of both the external ligands,Met andH2O2. This hypothesis
is consistent with the observation that Aβ1–40 has a higher tendency to
coagulate more than its short fragments upon metal binding.
The presence of the charge transfer band (Fig. 3) is indicative of
direct Met binding to the CuII center. This charge transfer transition is
consistent with a thio-to-CuII charge-transfer transition observed in
CuII-methionine complexes [61]. The Kd value of 11.3 μM deviates from
theKAc value obtained from the activity proﬁle discussed above (87 μM),
indicating that there are other factors that affect the Met binding to the
CuII center when monitored with activity, such as the cooperativity
discussed above (i.e., the formation of the reactive intermediate or
synergy due to multiple substrates). The oxidation state of a CuII center
in CuAβ1–20 uponMet binding can be concluded fromthe electronic and
EPR spectra, wherein the detection of d–d transition at 600-nm (Fig. 3)
and EPR features (Fig. 4A) indicate that CuII is not reduced by Met to
initiate the oxidative reaction. Met35 was previously suggested to be a
reducing agent which initiated the oxidation chemistry of CuAβ1–40
[17–22]. The observation herein is consistent with the kinetic results
that a Met, internal or external, is not needed for the metal-centered
oxidation reaction to take place (Fig.1). In the case of CuAβ1–40, the lack
of a Met-to-Cu(II) charge-transfer transition at ∼300 nm in the absence
of external Met clearly indicate the lack of interaction of the internal
Met35 with the metal center. Moreover, the addition of external Met
does not create a charge-transfer transition at ∼300 nm, but only a
shoulder concomitant with a change in the d–d transition. The results
indicate binding ofMet to themetal center of CuAβ1–40 does not change
the oxidation state of the metal center while the small afﬁnity constant
of 360 M−1 (Kd=2.8 mM) once again suggests a less accessible metal
center for external ligand binding.
The non-exclusive nature of Met and H2O2 binding to and additive
activation toward CuAβ1–20 indicate that there are two pathways for
the oxidation of dopamine in the presence of Met and H2O2, i.e., thepathways i–v and vii–iv–v with a bound Met (the “X” ligand in Fig. 5),
wherein the enhancement of the activity with Met alone is possibly
due to a non-redoxmechanism that ﬁne-tunes the reduction potential
of the CuII to favor the oxidative catalysis. The sigmoidal activity
proﬁles for dopamine oxidation in the presence of Met (Fig. 1A) and
with both H2O2 and Met (Fig. 1D) reﬂect a possible presence of
substrate-mediated cooperativity, such as the formation of the
dinuclear active center (Fig. 5; E). Despite the lack of a Met and any
redox-active amino acid, the fragments CuAβ1–16 and CuAβ1–20
exhibit signiﬁcant metal-centered oxidative activity [31,37,38] which
indicates that the redox role of Met35 might have been overstretched.
Instead, it may simply be a substrate during the oxidative catalyses by
metallo-Aβ. Moreover, the activity and optical studies of Met binding
and inﬂuence on the metal center in CuAβ1–40 further suggest that
Met35 may not necessarily be involved in the action of this Aβ
complex and its smaller 1–16 and 1–20 fragments.
The catalytic pathway of CuAβ1–20 is altered under reduction
conditions, wherein the reaction is locked into a H2O2-producing cycle
(iii and vi, Fig. 5). The competitive inhibition of ascorbate toward the
oxidation of dopamine by CuAβ1–20 may be because of possible
chelation and reduction of the CuII center by ascorbate. GSH may bind
to and reduce the CuII as a monodentate ligand which does not
prevent substrate from binding to the CuII center to form the inactive
inhibitor–CuAβ–substrate complex, thus exhibiting non-competitive
pattern (Fig. 2A). The inhibitory effect of these reducing agents toward
metal-centered catalysis is consistent with the proposed mechanism
wherein H2O2 is generated (step vi) [10,12].
The EPR spectrum of CuAβ1–20 can be attributed to a typical
tetragonally distorted CuII center, i.e., an elongation along the z axis
due to the Jahn–Teller effect. The EPR spectral features upon Met
binding to CuAβ1–20 conﬁrm the retaining of the d9 electron
conﬁguration of the CuII center. The lack of ΔMS=±2 transition, i.e.,
between theMS=−1 and +1 levels in an antiferromagnetically coupled
di-CuII center [62,63] in the EPR spectrum at low ﬁeld indicates
magnetic coupling between the CuII centers does not exist. Thereby,
the previously proposed [64] His-bridged dinuclear Cu,Zn-superoxide
dismutase center for CuAβ1–28 is not present in the case herein. The
dinuclear catalysis observed in the kinetic measurement must be a
transient state during the reaction in the presence of the substrate.
The small change in the EPR spectrum uponMet binding indicates the
charge transfer transition must be due to the binding of the thioether
of Met through the non-magnetic dz2 orbital at an axial position of
CuAβ1–20. Otherwise, more signiﬁcant changes in the g factor and the
A// tensor would be observed as reported for the binding of thio-
groups to Type-2 Cu proteins [65–69].
The ESEEM spectrum of CuAβ1–20 conﬁrms the binding of CuII to
Aβ1–20 through His side chains via the magnetic dx2−y2 orbital in
equatorial positions which gives rise to the quadrupole coupling with
the remote non-coordinated 14N on the coordinated His imidazole
ring. There are at least two coordinated His side chains as reﬂected by
the combination lines since a single coordinated His does not give rise
to these lines [66,70]. Very small η values are observed for the amine-
N of imidazole when H-bonding is scarce [71], which may be the case
for the coordinated His in CuAβ. The detection of a deuterium line at
2.29 MHz suggests the presence of at least one coordinated water (as
D2O), presumably in an equatorial position bound to the CuII via the
magnetic dx2−y2 orbital [43]. This signal is not much affected uponMet
binding, suggesting Met binding to an axial position. The signal at
4.6 MHz seems to be attributable to the double-frequency peak of two
or more coordinated water. The signiﬁcant decrease in the intensity of
this signal upon Met binding indicates that one or more weakly
coupled deuterium atoms in the CuII coordination sphere are replaced
upon Met binding.
Since the binding of Met to CuAβ1–20 does not reduce the CuII
center, the enhancement in activity must be attributed to a change in
the reduction potential of the CuII center. The axially coordinated Met
54 G.F.Z. da Silva et al. / Biochimica et Biophysica Acta 1792 (2009) 49–55ligand in blue copper proteins has been suggested to play a role in
controlling the reduction potential of the protein since mutation of
this Met results in a signiﬁcant change in the potential [72,73].
Similarly, the binding of Met to CuAβ1–20 may modulate the CuII/CuI
potential to favor the oxidation catalysis, yet is not necessarily directly
involved in the redox chemistry as a reducing agent. The oxidation of
Met35 previously observed may result from the metal-centered
oxygenation reaction discussed herein, i.e., Met binds to the metal
center (the X in Fig. 5) and serves as a substrate via step iv and v
without the catechol substrate. If occurred, this reactionwould be very
slow and beyond the detection limit under the conditions herein.
5. Concluding remarks
Although reducing agents can potentially inhibit the oxidation of
neurotransmitters such as dopamine by CuAβ1–20, yet not to the full
extent under physiological conditions [31], their capability in the
production of H2O2 may exacerbate the situation of oxidative stress.
Oxidation of dopamine to yield quinone can result inpolymerization of
tau protein into ﬁbrils [74,75] and covalent modiﬁcation of dopamine
transporter which directly affects dopamine uptake [76]. Since
dopamine plays important roles in behavior and cognition, such as
delay-period activity, memory, attention, mood change, pain proces-
sing, and motivation, as well as motor activity, long-term oxidation of
dopamine may be expected to render physiological and psychological
imbalance in the human brain. Moreover, the association of dopamine
motor activity and coordination seems to be a common factor thatmay
explain the Parkinsonian-like symptoms in AD patients. Hence, the
acceleration of dopamine oxidation via metal-centered mechanism
that can be modulated by small molecules such as reducing agents,
H2O2, and/or Met and Met-containing peptides suggests a signiﬁcant
role of CuAβ complexes in the mechanism of oxidative stress in the
brain of AD patients. The results herein further support the metallo-
ROS-centered redox chemistry of CuAβ1–20 [31,37,38] and provide
additional structural and mechanistic information for the oxidative
stress in the brain of AD patients. The role of Met35 has been redeﬁned
and the dual mechanistic roles of reducing agents (i.e., inhibition of
metal-centered oxidation and H2O2 generation) in the redox cycle of
CuAβ1–20 are clearly shown. Although CuAβ1–40 and its fragments
exhibit similar reactivities, subtle differences are still present which
suggests further investigations and comparison are needed for both
CuAβ1–40 and its fragments to gain a comprehensive understanding of
the molecular and mechanistic basis for their roles in AD. The overall
picture of AD neuropathology is likely to be composed of the pieces of
information uncovered thus far, including generation of ROS, metal-
dependent aggregation of Aβ, and the largely overlooked metal-
centered degradation of biomolecules. Treatment and prevention
strategies toward the oxidative stress in AD hence must address all of
these pathways, including inhibitions toward H2O2 production and
oxidative damage of neurotransmitters and other biomolecules by
CuAβ. Further studies targeted toward the elucidation of the metallo-
ROS species are being pursued to determine the species responsible for
the oxidative activity of CuAβ1–20.
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